Welcome to our dedicated page for Venus Concept news (Ticker: $VERO), a resource for investors and traders seeking the latest updates and insights on Venus Concept stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Venus Concept's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Venus Concept's position in the market.
Venus Concept (NASDAQ: VERO) announced its Q1 2024 financial results, reporting a 15% YoY revenue decline to $17.5 million, but exceeding its forecast by 6%. Operating expenses dropped 11% to $19.4 million, while the net loss was $9.8 million, slightly higher than Q1 2023's $9.7 million. The gross profit fell 15% to $11.6 million with a consistent gross margin of about 66.6%. Notably, cash operations used $2.9 million, a 51% reduction from the previous year. The company secured $5.0 million in debt financing from Madryn Asset Management to enhance near-term liquidity. Strategic milestones include the TGA clearance in Australia for Venus Versa Pro and approval for Venus Bliss MAX in Israel. Venus Concept forecasts Q2 2024 revenue to be at least $16.5 million.